Phase 1Not yet recruitingAge-related condition
Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS (ROAR HMB)
A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
- Sponsor
- Duke University (Academic or other)
- Enrollment
- 100 planned
- Conditions
- Amyotrophic Lateral Sclerosis ALS
- Interventions
- β-hydroxy-β-methylbutyrate (HMB)
- Ages
- adults, older adults
- Registry
- NCT07589764
Full record on ClinicalTrials.gov
From the registry
This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating Scale, Revised (ALSFRS-R) progression.
Primary outcomes
- ALS Functional Rating Scale, Revised (ALSFRS-R)
- Speech (Listener Effort)
History
Primary completion expected
Expected to start
Last registry update
Registered